Showing results (221-230 of 423) with videos related to

Sort By:
Pageof 43
JAMA Cardiology|December 10, 2025
Rationale, Design, and Baseline Clinical Characteristics of the Ziltivekimab Cardiovascular Outcomes Trial: Interleukin-6 Inhibition and Atherosclerotic Event Rate ReductionPaul M Ridker, Florian M M Baeres, Anders Hveplund, et al.
Diabetes Care|December 4, 2014
Efficacy and safety of canagliflozin, an inhibitor of sodium-glucose cotransporter 2, when used in conjunction with insulin therapy in patients with type 2 diabetesBruce Neal, Vlado Perkovic, Dick de Zeeuw, et al.
Diabetes, Obesity & Metabolism|February 15, 2022
Cardiovascular and renal outcomes with canagliflozin in patients with peripheral arterial disease: Data from the CANVAS Program and CREDENCE trialJennifer Y Barraclough, Jie Yu, Gemma A Figtree, et al.
The Lancet. Rheumatology|January 17, 2024
The effects of canagliflozin on gout in type 2 diabetes: a post-hoc analysis of the CANVAS ProgramJingWei Li, Sunil V Badve, Zien Zhou, et al.
American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation|June 15, 2012
Prediction of kidney-related outcomes in patients with type 2 diabetesMeg J Jardine, Jun Hata, Mark Woodward, et al.
BMJ Open|February 21, 2019
Randomised controlled trial of the impact of haemodiafiltration on uraemic neuropathy: FINESSE study protocolBrendan Smyth, Arun V Krishnan, Martin Gallagher, et al.
Diabetologia|March 15, 2019
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS ProgramDavid R Matthews, Qiang Li, Vlado Perkovic, et al.
The New England Journal of Medicine|May 24, 2024
Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 DiabetesVlado Perkovic, Katherine R Tuttle, Peter Rossing, et al.
Journal of the American Heart Association|January 30, 2020
Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-AnalysisClare Arnott, Qiang Li, Amy Kang, et al.
Diabetes Care|October 4, 2013
The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetesGraham S Hillis, Paul Welsh, John Chalmers, et al.
Pageof 43